Welcome and Introduction (ID 4807)
Enhancing the Clinical Application of Biomarkers in the Management of NSCLC (ID 4808)
State of the Art in Immunotherapy for NSCLC: What Is the Current Evidence in First-line Treatment? (ID 4809)
Translating Clinical Data Into Practice: Considerations for Immunotherapy in Specific Patient Populations (ID 4810)
Case Discussion (ID 4811)
Ask the Faculty and Concluding Remarks (ID 4812)
